PD

britash1229

THE PDL-1 up regulation discovery has sealed the fate of cytodyn and its trajectory‼️🙌🏼 The checkpoint inhibitor companies (MERCK , ROCHE,ect) only been able to treat 15% of solid tumors, which are PD 1 positive , will now be able to treat the remaining 85% that a PDL1 negative‼️ We are talking about over 30 types of solid tumors ‼️😆This Is mind boggling. The five women that are still alive from the compassionate you study ,from five years ago ,that received Leronlimab + checkpoint inhibitors are disease free. THERE BRAIN METS ARE GONE‼️. DR. JAY HAD DINNER WITH ONE OF THEM AND WAS SO EMOTIONAL.

britash1229

THE PDL-1 up regulation discovery has sealed the fate of cytodyn and its trajectory‼️🙌🏼 The checkpoint inhibitor companies (MERCK , ROCHE,ect) only been able to treat 15% of solid tumors, which are PD 1 positive , will now be able to treat the remaining 85% that a PDL1 negative‼️ We are talking about over 30 types of solid tumors ‼️😆This Is mind boggling. The five women that are still alive from the compassionate you study ,from five years ago ,that received Leronlimab + checkpoint inhibitors are disease free. THERE BRAIN METS ARE GONE‼️. DR. JAY HAD DINNER WITH ONE OF THEM AND WAS SO EMOTIONAL.

darlenesapira

Best Results from CYDY (Leronlimab) Trials – Summary HIV (Combination Therapy & Monotherapy) 1) Achieved primary endpoint in Phase 3 trial for treatment-experienced patients. 2) Some patients on monotherapy maintained viral suppression for years. COVID-19 (Severe/Critical Cases) 1) Phase 3 data showed reduced mortality and faster hospital discharge in critical patients vs. placebo. NASH/MASH (Liver Disease) 1) Phase 2 (open-label):  50% of patients showed ≥80ms reduction in cT1, a key marker of liver disease severity. Preclinical data showed reversal of fibrosis and liver fat reduction. Metastatic Triple-Negative Breast Cancer (mTNBC) 1) In small subgroup, 15/17 patients on ≥525 mg dose showed increased PD-L1 expression (potential synergy with immunotherapy). 2) Some long-term survivors (up to 4 years with no evidence of disease). Metastatic Colorectal Cancer (MSS, CCR5+) 1) FDA cleared Phase 2 trial design combining leronlimab with TAS-102 + bevacizumab. Trial to assess ORR and safety. Promising. Something for the longs to feel hopeful in seeing.

britash1229

Leronlimab is a game-changing in the fight against HIV and ALL SOLID TUMORS, and it’s finally getting the attention it deserves. For years, many believe its potential has been overlooked or even suppressed by big pharmaceutical interests. Now, recent findings suggest leronlimab upregulates PD-L1, which could dramatically improve the effectiveness of existing immunotherapies for cancer — potentially helping the 85% of patients who previously didn’t respond. This shift could turn what was once seen as competition into collaboration, with major pharma companies standing to benefit as well.

twinter11

Thank God for snap judgements. All the reasons typically quoted for why to avoid something It allowed me to buy a lot of shares before it becomes obvious whats gonna happen. But when there is a good chance to cure (I know, strong word ) possibly some large percentage of currently non treatable cancers with the addition of ICI's, and data coming in slowly is supporting its going to be reality. It becomes obvious with 30 minutes of research focusing the relevant released data, that there is virtually zero risk investing at this price I think. Heres an article with a quick synopsis that says it better than me. [https://talkmarkets.com/content/stocks--equities/cydy-this-penny-stock-keeps-looking-better-coming-into-summer?post=500795](https://talkmarkets.com/content/stocks--equities/cydy-this-penny-stock-keeps-looking-better-coming-into-summer?post=500795) And a previous article from the same guy. Its a super deep dive with TAM's and financials and company history etc. That mostly becomes irrelevant once they upregulate PD-L1 in all solid tumor ccr5+ cancers and qualifying them be be treated with ICI's. [https://talkmarkets.com/content/stocks--equities/when-penny-stocks-can-become-compelling-a-long-term-buy-with-cydy?post=489422](https://talkmarkets.com/content/stocks--equities/when-penny-stocks-can-become-compelling-a-long-term-buy-with-cydy?post=489422)

twinter11

I did a quick scroll through some posts on another board. this guy knows quite a bit about everything known about ccr5 agonist. here is how he described it. but I'm sure its more complicated than I can explain. "A mistaken impression I've seen here several times. Tumors are considered hot because they have a high immune response in other words a very high levels of M1 killer macrophages and natural killer T-cells. PD-L1 doesn't exist in cold tumors because PD-L1 is a response to a high level of killer macrophages and NKT cells. PD-L1 may be considered a marker of a hot tumor but only because the killer macrophages induce PD-L1 proliferation. Ideally a hot tumor would not upregulate PD-L1 which protects the tumor, but that's not how it works because the immune system is trying to balance out the over-representation of killer cells. When leronlimab increases the M1 macrophage phenotype it results in an increased level of PD-L1 which must be knocked down for the killer cells to do their work most effectively."

Acceptable_Ad_4193

“Finally, I am happy to share a very promising announcement as it relates to a patient who prospectively upregulated PD-L1 after having obtained access to leronlimab through an eIND application submitted by her treating physician. In early 2025, we received a compassionate access request for a patient with mTNBC who was previously unresponsive to treatment with Keytruda. This particular patient had two prior tissue biopsies, both of which were PD-L1 negative. In April, the patient started treatment with leronlimab, and in July blood tests confirmed an increase in PD-L1 levels. Our past clinical observations have shown that upregulating PD-L1 is the first step towards prolonged survival in this patient population and we are encouraged by this readout, which supports our working theory. This is the first of hopefully many PD-L1 upregulation readouts across our CRC and TNBC trial(s) in the coming year. I continue to have high hopes for our upcoming Phase II trials, as well as our expanded access program, as we look to reshape treatment paradigms in solid tumor oncology.”

twinter11

I linked the recent abstract. it's pretty brief. Abstract B019: CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC. | Cancer Immunology Research | American Association for Cancer Research [https://share.google/8UaIrAve4hzZJ0qBE](https://share.google/8UaIrAve4hzZJ0qBE)

PruneReady7081

Im an immunologist, and I follow this with quite some interest. Just to note that ive no positions in this company at all, and ive no intention on taking up any. This comment is purely on a scientific perspective, and i’ve no idea how that translates to share prices. Ive never heard of this idea in converting a cold to hot tumor by promoting the activation of the very axis (PD1-PDL1) that is central in causing the coldness to begin with. I’m skeptical, but find this strategy very interesting and will follow these trials with keen interest. I think the efficacy of the drug will be fairly dependent on the immunological context of the drug to begin with. Since the cancer is metastatic and TNBC, i would suspect that any PD-L1 expression in the tumor would be the case of active immune suppression by the tumor, and not the upregulation of the axis by immune cells upon exhaustion post immune stimulation. In this context, i wonder if ‘helping’ the tumor upregulate PD-L1 would be a good idea. Of course, the propf is in the pudding and i’d be happy to have my skepticism disproved! Some other things im curious about. They note 42% reduction in combination with endocrine therapy. TNBCs are, by definition, refractory to eendocrine therapy since they lack the expression of hormone receptors (hence, triple negative). Are they suggesting their drug is also re-activating endocrine pathways? That would be interesting, and would need more clarity. I am also very curious about their data on CTCs. There’s this seed and soil hypothesis with CTCs, which suggest that CTCs are crucial in seeding distant metastatic organs with the appropriate factors to make it favorable for metastasis. So how good of an idea is it to be targeting CTCs after metastasis has occured? Could the CTCs maybe also have important roles in sustaining the metastatic tumor, making them a good therapeutic target? Or perhaps, this drug is highly effective in early TNBC? I’m not too sure, but given the aggressive nature of TNBC, any drug in this space must consider the limited amount of time available to suppress the cancer, and I would hope the strategy that targets CTCs would not be a case of showing up to the fire after the house has burned down. Overall, I think its an interesting case, and im excited from a scientific perspective to see if the hypothesis behind this drugs mechanisms of action will bear fruit. Of course, an obligatory, this is not financial advice. Im just nerding.

Ok-Recording4145

chemo drugs are very hard to classify this early-- although it does something good (PD-L1 upregulation) it's really anyone's guess what it does systemically otherwise. Less than 10% of chemo drugs go from Phase I to market for a reason. I would take a flier on it since it's so low but keep in mind the Phase II results could be very disappointing.

Simple-Knowledge-411

On the 15th, IBKR raises the margin on leveraged ETFs. If the leverage says x2 and the margin is 25%, they raise it to 50% based on the 2 x 25 rule. I hope I don't get a margin call on the 15th. Aside from the fact that it's a shitty broker that didn't allow me to trade, AND I could have made 200% in 2 days. PD: UNNISTALL BRO

C3POmeetsR2D2

Iovance Biotherapeutics is a biopharmaceutical company specializing in cell-based immunotherapies for cancer, particularly tumor-infiltrating lymphocyte (TIL) therapies. Here are the key points about what Iovance produces/develops: What is TIL therapy? Tumor-infiltrating lymphocytes are immune cells (T cells) that are found in tumors and have the potential to recognize and attack cancer cells. In this therapy, such cells are removed from a patient's tumor, multiplied ex vivo, "reinvigorated," or activated, and then reinjected into the patient. [iovance.com](http://iovance.com) This usually includes preparatory chemotherapy (lymphodepleting) and, if necessary, additional interleukin-2 (IL-2) to support the effect of the T cells. Products and Pipeline Amtagvi® (active ingredient: lifileucel) is Iovance's lead product. It is a TIL therapy for the treatment of adults with unresectable or metastatic melanoma when previous treatments with PD-1 inhibitors (and, if relevant, with BRAF inhibitors for BRAF-mutated tumors) have failed. BeyondSPX They also have Proleukin, a product with IL-2 that is used as an adjunct in therapy. [Investing.com](http://Investing.com) Other programs in the pipeline: IOV-4001: genetically modified TIL in which, for example, the checkpoint protein PD-1 is deactivated (using TALEN technology). The goal is a more effective TIL therapy for solid tumors. [iovance.com](http://iovance.com) IOV-3001: an IL-2 analog/antibody cytokine construct licensed from Novartis to enhance the IL-2 component of the regimen. [https://www.wsj.com/market-data/quotes/IOVA/research-ratings](https://www.wsj.com/market-data/quotes/IOVA/research-ratings)

robbur88

So I see these sometimes and it throws me off. Same description but, in this case, very different stock prices GPUS vs GPUS/PD?

2MuchSend

Alright boys and girls, weekend is here. Alcohol is great until it isn't. Drinking and driving is a big no-no. Best case scenario, you look like an ass hole. Worst case scenario, you get in a head on with a family driving home from a nice dinner and create a few orphans and then get to enjoy the rest of your life with your new friends Bubba and d-boi. I know that you know that if you've got the cash to yolo on 0DTEs then you can afford the Uber. Look out for yourself and look out for others. Homie got the nose beers? Test that shit. Imagine the local PD having to tell your family that you OD'd on bad booger sugar. Don't add to the population. Don't subtract from the population. Avoid confrontation, be cool, de-escalate, only fight if you have to and if you have to win and get the fuck out. Every one knows something these days, nerdiest guy in the back office probably has a blue belt and if he doesn't, he probably has a piece. Hope to see you all on Monday.

TheSoarsCode

Is it just me or did ATCH just blink from .63 to .65? 

CertainFan7743

The monthly dividend stock of GPUS is a preferred issue GPUS-PD trading above $23 a share

bubbasnub

He's about to have enough to just buy the PD outright

Brilliant_Law2545

I didn’t say they aren’t successful. Most folks here looks for a growth engine and PD ain’t it.

megadalon

PD just shitting itself last few days

naked_space_chimp

Alright ASSHOLES! You wanna make some money! Here are my plays: * $ASAN 🐻 | 20 Sep ATM PUT @≈$12–$14 — play the 85% IV crush on this SaaS dumpster fire. * $NIO 🐂 | 13 Sep ATM CALL @≈$7–$9 — bet on the EV hype train derailing post-earnings. * $LULU 🐻 | 20 Sep 190 PUT @≈$8–$10 — actual downside play from $202 spot, retail puke incoming. * $PD 🐻 | 20 Sep ATM PUT @≈$6–$8 — SaaS turd ready to dump and vaporize IV. **Exit at +100% or -50%.** These are pure **volatility** plays, GTFO from the trades, don't fall in love with direction.

No-Western-9331

It is profitable if you catch it in time. I actually bought more at low price to avoid out better. And now waiting for pump. What does a PD pattern look like?

No-Western-9331

I was scammed in last PD cycle via wats app group. Came out early or would have lost 50k. Looking and its last 3 PD cycles im hoping it may pump again so I can exit with some profit. I have 6000 @1.9. Any ideas or suggestions how to predict a pump?

No-Contribution1070

I mean, the individual national guard member is technically also a citizen. If a citizen breaks a law in chicago, the can be arrested by local PD. It's interesting for sure.

saryiahan

So does that mean we would see local PD arresting national guard members?

Harooooouuld

ZS, PD, GTLB are probably the best bets for next week but early September could start with some red. FIGMA is either going to launch higher to screw any put holders or be a theta play. I say that even with a high PUT/CALL ratio because this seems to always happen with new IPOS. They move down more outside earnings weeks.

Spankynpetey

You must not be paying attention, top Republicans have already introduced a bill to regain authority over tariffs and remove those powers granted to the executive by prior congressional actions and the same is pending before the US Appellate Court because the Federal ICC found the current tariffs exceed the authority of the executive and constitute unconstitutional acts. The only hope Trump has of avoiding impeachment is complete and total martial law which is why he tested the military with occupation around the federal courthouse in LA and is now supplanting the District of Columbia PD. These are the steps he thinks will gain him complete totalitarian authority, but the strands of power have begun to unravel and he knows it. News channels walk a tightrope afraid to cover it in fear of retribution but the wheels are turning, the cogs of his downfall are in motion. Nobody is beyond reach…

DumplinButt

You have to remember there are limits in insurance. So if he has 10k of PD limits then the insurance company will only pay a maximum of 10k for the damage to the rivian and the insured is on the hook for the rest. Same with Bodily Injury limits, there are maximums for those as well.

Specialist_Jelly888

You really think the local PD is going to be of any assistance on something like this? Seriously?

Key_Ad7977

What's your avg $RAYA? Sure, it can go. Every ticker can go no matter the circumstances. Ok very fast check $RAYA havr better cash position, they get in more then they spend, $CHSN seems like had debts. But was probably because of that they did the dilution, but it's over now. BUT $RAYA have RS coming which don't attract investors like you probably already know, else you need to change interest or learn more. $CHSN DON'T have any RS coming, no planned shareholders vote meeting planned to decide about RS (that's known about. I would definitely say $CHSN it's in a much better position for a well either PD up to 0.20-22.5, or a mice squeeze up to 0.50. No matter what THIS is not a financial advise!

DiskAlternative9854

China 🇨🇳 classic PD

DiskAlternative9854

Hopefully not PD today, expect $2.5 then I am out.

Practical-Tennis-508

If NuCana is currently in Phase 1, has a catalyst date in August 2026, and met with the FDA in June 2025, it is likely that the company is planning or has recently completed discussions with the FDA regarding the regulatory pathway and pivotal trial design for its Phase 1/2 candidate—specifically NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant melanoma. Based on NuCana's recent communications, the June 2025 FDA meeting was expected to provide regulatory guidance for a pivotal registration trial of NUC-7738[3](https://www.nucana.com/downloads/NuCana02JUNE2025.pdf). The August 2026 catalyst likely refers to the anticipated timing of either a major clinical trial readout (such as final data from the expansion or pivotal trial) or a key FDA regulatory milestone like the acceptance of a New Drug Application (NDA), subject to successful clinical results and further guidance from the FDA. Essential context: * NuCana's press release from June 2025 stated its goal to "obtain regulatory guidance from the U.S. Food and Drug Administration on pivotal study design for NUC-7738 in melanoma," with final data from ongoing studies expected within 2026. * The drug remains in Phase 1/2 as of mid-2025, with expansion trials underway and no pivotal trial initiated yet. * The "catalyst date" in August 2026 could thus represent (depending on FDA feedback and clinical progress): the start of a pivotal Phase 2/3 study, a data readout from a key expansion cohort, or submission of a regulatory filing (NDA/BLA) if accelerated pathways are pursued. Regulatory and developmental progress will depend on outcomes of ongoing studies, FDA feedback, and successful patient enrollment. The August 2026 date marks a critical value-creating milestone for investors tracking NuCana's clinical and regulatory trajectory.

manomus

this the entire market a PD

Straight-Annual8687

multicam hawaii livestreams with PD and fire dispatch in background (unsure which agency/island the dispatch is for). So far, meh as you'd expect [https://www.youtube.com/live/TfpuAwCQmGQ](https://www.youtube.com/live/TfpuAwCQmGQ)

Spidyyellowfish

I thought so too! Saw this as a chance to ride the momentum of the evil corporate overlords while pressuring their margins and championing PD

Virtual-Bid-1728

Man, u hit the nail right on the head! Seen the same thing go down at a few places I worked. They swoop in, squeeze out every last penny, leave the place a ghost town. TBH, it sounds like PD's exactly their type. Got a sinking feeling in my gut, but hey maybe we can make them sweat a lil', right? Upvote from me dude, this needs visibility!

Spidyyellowfish

Pagerduty is in a similiar boat with talks of a sale catalyzing a squeeze. Two good ones. PD is going pretty unnoticed also

figlu

issue is that they tested the drug (PD-L1 silence) in cSCC which rarely metastasize and the treatment of choice is local resection. Metastatic disease is treated w/ PD-L1 antibodies. Where will this drug be used?

SlackBytes

Why is $PD up?

cat1254

Based on the latest data, **$NCNA** is shaping up to be a **high-risk, high-reward play** with explosive upside potential, especially heading into **August 8.**   **📈 Short squeeze score**: **97.92/100**, one of the highest in the market **🔥 Technical Setup** * **Float shrinking** from \~381M to **\~1.9M shares** post-split * **Short interest >100% of float**, with borrow fees still above 21% * **Fails-to-Deliver (FTDs)** from July 9’s 1.81B volume day are likely being forced to settle now **🧬 Clinical Momentum** * **NUC-7738**: 75% disease control rate in PD-1 resistant melanoma * **NUC-3373**: Tumor reductions in solid tumors and lung cancer * **FDA engagement** expected later this year **🧠 My Take** If the reverse split executes cleanly and clinical data continues to impress, $NCNA could become one of the most dramatic biotech turnarounds of 2025. But it’s not for the faint of heart - volatility will be extreme, and timing is everything.

Fate916

Never too late we’re waiting for these news to drop in any days; Regulatory approvals for Amtagvi "expected" in the UK, EU, and Canada in 2025. Regulatory submissions remain "on track" for Australia in the first half of 2025 and Switzerland in the second half of 2025. Patient enrollment in TILVANCE-301, Phase 3, continues. Additional data for IOV-LUN-202 post-anti-PD-1 NSCLC "on track" for 2nd half 2025. "Initial results" for IOV-END-201 endometrial cancer "expected" 2nd half 2025.

yellowLantern

I worked in oncology for mid-size and big pharma. This data is not as compelling as you think it is. 1. This is Ph1b data with very small sample size. It's not registrational, many things can go wrong before the drug is approved. 2. The outcomes you point out are the weakest surrogate outcomes for oncology (ORR-objective response rate). Company released some data for mPFS and mOS, and they seem okay for a post-PD1/PDL1 setting but again the small sample size makes the data unconvincing. 3. You need to think about the population being treated and thus the potential revenue. The studies are post PD1/PDL1 metastatic melanoma, which cuts down on the eligible patient population. Uveal melanoma is a nothingburger, it's about 5% of metastatic melanoma and maybe 1-2k cases a year are diagnosed in the USA. 4. Melanoma trials are long. It can take years for the Ph3 to read out and be approved. I'm not sure if I saw this company has an accelerated approval strategy. 5. Approval is only the first large barrier, the second is getting utilization and reimbursement from the insurance payers or adoption by the clinical guidelines/pathways that guide access. Without these revenue will falter. As such, there's still a long lead up time to both approval and profitability. A lot can happen (both good and bad) in between then.

SlackBytes

Pagerduty $PD. It’s only $1.4B market cap. It’s a tech company and they have no competition. They specialize in paging systems. And well I guess every company needs some users with it and they’ll eventually adapt Pagerduty.

Nusanss

they're actually showing slightly better numbers than the current standard. Casdozokitug combo is showing 38% overall response rate with 17% complete responses in liver cancer. Keytruda + Avastin (current standard) shows \~36% response with \~12% complete responses. So marginally better, but here's the real play: They're attacking different mechanisms. Keytruda blocks PD-1 (removes the brakes on immune cells). Casdozokitug blocks IL-27 (removes the tumor's "invisibility cloak"). CHS-114 kills regulatory T-cells that protect the tumor. Think of it like this - Keytruda is a sledgehammer that works great for some patients. Coherus is building targeted tools for the 60%+ who don't respond to Keytruda. The smart money isn't on beating Keytruda head-to-head. It's about capturing the patients where Keytruda fails. Even 10% of the liver cancer market = massive returns at current valuation. Plus if that 17% complete response rate holds in larger trials, Big Pharma will come shopping. Different mechanism + better complete response rate = acquisition bait. TL;DR: Not trying to replace Keytruda, trying to fix what it can't. At negative enterprise value, they don't need to win the whole market to print tendies 🚀

richbeezy

Shitty stocks that rose today for the sole reason of being heavily shorted. Ones that you could and should buy puts on: -ANGI -REAL -GEO -RUM -PD

jorge-emilio

I'll answer your question using the four points that I established in one of the yellow notes. The four points are the following: 1. Macro trend (is it clearly bullish or bearish?). 2. Macro PD Array (are there one or more PD Arrays that align with the macro trend?). 3. Micro signal / Mathematical logic (this would be your personal entry technique on whatever timeframe you use). 4. Trade the momentum that favors the macro trend (go with the macro trend, not against it). These are the criteria that I look/wait for in order make a high-probability decision. \*\*\* This is not financial advice and should not be used or considered as financial advice.

En_CHILL_ada

https://youtu.be/PD5gtM1A990?si=pHsdOLr7PzU6yRb3

Ikeelu

I also some one slow down for a deer crossing the street today and slow down to cautiously pass PD. The deer didn't show up on camera though which was surprising it still slowed down not registering it as an object on screen.

richbeezy

Here's the kicker, when markets get overbought (which they are getting close to), you keep your shares in high growth "Chad" stocks - but also buy lots of puts on SHITTY companies like BMBL, LUMN, REAL, GEO, RUM, PD, etc). Shitty stocks that are in a 5 year downtrend. Therefore, if the market keeps going higher - these shitty stocks will still struggle in comparison. Then when the market truly turns, these puts will print. The ones I have are out to 10/17, plenty of time for a correction between now and then and markets tend to trough in early/mid October. Yes, I've been doing this for a long time (almost 26 years now).

Possible_Cheek_4114

https://www.businesswire.com/news/home/20250618276691/en/FDAs-Approval-of-Keytruda-for-PD-L1-Positive-Head-and-Neck-Cancer-Patients-Signals-a-Clear-Pathway-for-CEL-SCIs-Multikine-to-Address-a-Major-Unmet-Need-in-PD-L1-Negative-Cancer-Patients

smutmybutt

I would say that example just proves that the Baltimore PD is fucking stupid. Any ineffective system can recommend people to arrest. I think Musk and Thiel are capable people who have compromised their own capability by falling so deeply into their ideology, self-absorbed echo chamber, and worst instincts (although Elon has the most publicly available evidence to back up this claim). In the case of Elon he has a long-term addiction to drugs that are negatively impacting his brain. There was also evidence of Elon being a bad manager in his “golden years.” His main talent was being a bully with VC money. By most accounts he was basically kicked out of PayPal. If Elon was smart he wouldn’t have needed to support the anti-EV party in order to avoid SEC trouble. If he was smart he wouldn’t have alienated his main customer base for Tesla, running the only EV brand with declining sales. If he was smart his multi-year head start producing cars in China would lead to his vehicles beating out BYD and other Chinese competition (companies run by smart people like Apple have no problem maintaining their first mover advantage in China).

North_Ad_4609

Just a PD my guy

richbeezy

Give me a few shitty stocks to buy puts on (out to 10/17). I already have 2 good ones (BMBL & PD). I am looking for weak stocks with little future growth. Not an over-valued tech play, as they still have nice growth.

No_Feeling920

Just in time for this regarded bean counter leadership kicking in. Like it ended well the last time INTC tried it. Truly regarded... [https://www.digitimes.com/news/a20250609PD227/intel-gross-margin-profit-policy-business.html](https://www.digitimes.com/news/a20250609PD227/intel-gross-margin-profit-policy-business.html) They will be wishing to have kept Gelsinger a couple years down the road.

Same-Brilliant2014

Live PD is already back

Danyzinho29

Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer’s disease and Friedreich’s ataxia – both of which have limited therapeutic options. Voyager’s lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer’s disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer’s research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure. Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer’s. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026. The promise of Voyager’s TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich’s ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones. Source: TipRanks

the_whole_arsenal

By waiting in the wings, you mean 3-4 years before it reaches its next-generation phase design, 5-6 years before it is on the wing of a plane, and 8 years before it is certified outside China, right? From what was said about it at the Dubai Airshow in 2024, the first-generation engine has serious power deficiency issues. It needs 28,000 lbf to make the c919 airborne, and testing has it in the 25,000 to 26,000 range. The LEAP engine produces 30.8k to 31.6k lbf in thrust depending on the model. The CJ-1000A is closer in architecture to the CFM-56-5 (an engine designed 38 years ago) than the LEAP with an 8.5x bypass ratio and suggests it would be limited to ~27,000 max thrust. China would honestly be better off contacting United Engine Corp (Russian) and offering a boatload of cash for a turnkey design to build the Aviadvigatel PD-14 under contract. It is 6-8 years more mature in design than the CJ-1000A, but I'm sure I'll hear a lot about both next week in Paris.

Formal-Industry-5243

I recently came across a relatively small biotech company called Faron Pharmaceuticals (FARN on AIM, FARON on Nasdaq Helsinki), and I wanted to share some thoughts and hear opinions from others who follow the biotech space. Faron is a Finnish biotech company developing immunotherapies for the treatment of aggressive cancers and inflammatory conditions. Their lead candidate, bexmarilimab, is a macrophage-targeting antibody (anti-Clever-1) currently in clinical trials for several types of solid tumors, including NSCLC, HNSCC, and melanoma. The early data from the BEXMAB trial (combination with anti-PD-1/L1 therapies) shows some promising responses in difficult-to-treat cancers. Here are a few points I found interesting: • Unique Mechanism: Bexmarilimab aims to reprogram tumor-associated macrophages (TAMs), potentially enhancing the patient’s immune response against cancer. • Small Cap: The company is still quite under-the-radar, with a market cap under €200M, which leaves room for volatility but also upside. • Funding: Like many small biotechs, they face financing risks. They’ve had a few rounds of fundraising, and dilution is a concern. • Upcoming Catalysts: More clinical readouts expected in 2025 – could be make-or-break depending on data. I’m curious: • Has anyone here been following Faron? • Thoughts on the BEXMAB trial or the TAM-targeting approach? • Is this a potential hidden gem or just another risky small-cap biotech? Would love to hear others’ DD or bear/bull theses!

Beneficial-Swim843

Yeah, because there aren't any names that aren't pennies that move far more often and more significantly LMFAO  NTAP, PATH, ESTC, PD, AMBA, MRVL, AEO, ULTA, ZS, etc. https://preview.redd.it/2ll26rsvbx3f1.png?width=495&format=png&auto=webp&s=180b56205e500bab6ad7bd85cef4231c0a33cfdc

richbeezy

Bought PD puts. Who even uses a pager any more???? /s

richbeezy

PD (been in biz for so long and struggles to make profits in an environment/sector where it should be easy). BMBL - no need for explanation. DIS - dying company, chart looks like 💩 JETS - airline ETF, ppl are flying less overall. QBTS - bought puts Friday, just over-valued short/intermediate term.

f0xinaround

Campus pd or live PD?

richbeezy

Bought some puts on DIS, QBTS, JETS, and PD. Just hedging my long portfolio.

Gloomy_MTTime420

Yes, you have to go alone and setup your own Discord server. It’s the only way! This chat sucks, feels like it’s been taken over by bots, young inexperienced investors, PD guys like that GodMyShield clown, or the same two people answer everyones’s posts (which by its very definition becomes homogenized). And most people here imo (and no offense to those of you this applies to), have absolutely zero clue what they are doing. Would you take driving lessons from a 7yr old that just learned how to ride a bike without training wheels? Yeah, it’s like that.

BenisSpaghetti

This is why you must stay vigilant and report any 🐻 activities to your local authorities. I reported my coworker after he said he won't be able to retire due to being 'out of the market'. Luckily the local PD came by and shot him in the back of his head while he was working. Solved that retirement problem for him! 

Gloomy_MTTime420

If you are attempting to trap retail traders in an upside down OTC stock, keep listening to all the PD about $DMN!

Gloomy_MTTime420

At least the pennystock sub has better picks than the constant stream of PD posts from shortsqueeze.

IdealShot7890

and still not getting the love here. we are all busy chasing risky Chinese PD plays

Kestrel19

I just did a quick read and the two (ANVS & AVXL) are different in target molecules and mode of action. ANVS is effectively an mRNA inhibitor. go to wiki to learn about Blacarmesine. My own view is the mitochondria play a substantial role in PD. Hopefully we will one day see a pinch of Blacarmesine added to Buntanetap in a trial.

jefbe80

7:09 AM EDT, May 06, 2025 (Benzinga Newswire) License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity. "We are pleased to expand our portfolio of licensed patents and add a technology that uses REQORSA to treat glioblastoma," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. "With this license agreement, Genprex has obtained exclusive commercial rights to REQORSA in glioblastoma while also adding to our patent estate. The role of TUSC2 in lung cancer has been well established, and this latest license enables Genprex to expand the use of REQORSA into a new indication, in which the cancer can be difficult to treat and there are unmet medical needs." REQORSA may be a potential therapeutic treatment for glioblastoma. Genprex previously reported positive preclinical data on the efficacy of REQORSA in glioblastoma in October 2024 at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Research collaborators from UTHealth Houston previously reported TUSC2 as a novel tumor suppressor for glioblastoma, the most common and deadliest primary brain tumor in adults which is associated with a poor prognosis. In their latest study, UTHealth Houston researchers used patient-derived glioblastoma (GBM) cell lines and patient-derived glioma stem cell (PD-GSC) lines. REQORSA was used to restore TUSC2 expression. Write to Benzinga at editorial@benzinga.com

Duke834512

Didn’t he fire Jeff Bridges the first time around for threatening to do that shit? I vaguely remember the Keebler Elf threatening legal states and getting salty when they threw up the finger and said “The DEA won’t have any help from local PD” Could be misremembering though

YamahaRyoko

It was our PD's #1 probable cause tool. They even pleaded on Facebook not to vote for legalization, claiming they have "never bullied the public with it". Yeah right lol

JohnLaw1717

Iirc robotaxis are just a taxi service using normal Tesla's. That deploys in a couple weeks in Austin. They already hired the drivers and Austin PD has had press conferences and stuff. You're probably trying to joke about cybercab. Thats the vehicle specifically designed for being a taxi. It's unconfirmed but there's drone footage of hundreds of chassis or frames rolling out to the Tesla factory yard for initial testing already.

narrowant34

They are yapping that leather jacket man is considering spinning off his company's Chinese operations or establishing a joint venture in China. [Link](https://www.digitimes.com/news/a20250428PD215/nvidia-jensen-huang-ai-chip-china-geopolitics.html) [Link1](https://x.com/Jukanlosreve/status/1916740717638029503) 

mmcmonster

This is one of those things that really depends on when your starting points are. Here is [Gold vs. US Stock Market since 1980](https://testfol.io/?s=7BBKer6sBhf). Here is [Gold vs. US Stock Market since 2000](https://testfol.io/?s=b56APv2PD49). Here is [Gold vs. US Stock Market since 2020](https://testfol.io/?s=9PoWJUAUES3). Make an [Investor Policy Statement (IPS)](https://www.bogleheads.org/wiki/Investment_policy_statement) and stick by it. It's not as sexy as buying high and selling low, but it will do you better in the long run.

ChairmanMeow1986

Soo, if you don't grasp PD.T I'd say don't day trade on margin. if you don't understand something it is time to learn.

hynekien

https://x.com/unusual_whales/status/1914794137997476134?s=46&t=AX7Lo0mD5PD0A7kSIgJZ4w

jxx37

Obviously you also need SW to support HW--the critical speed difference is the dedicated HW build. Most of the people from the HW side that who moved to high speed trading work on FPGAs. Interestingly one of the big companies in the field recently hired a full digital PD team with 4nm experience so at the minimum they are exploring doing custom silicon.

warlock22041

I have been paged 4 nights in a row. If I get paged one more time tonight, PUTS ON PagerDuty PD 

tenpenny3

As someone in the food tech space, Wendy’s has a really good app. While McDonald’s app is OK but their loyalty and overall complexity holds them back. Notice that wendays has in-store (or at least close to it) pricing while McDonald’s still uses their 3PD pricing? McDonald’s App is a mess. Their app is hard to navigate, their loyalty shit, and their app pricing makes a DoorDash dash pass make sense (not a good thing for first party).

wiggitywoogly

Paradise PD did it, why can’t we?

geneing

I don't think the trade deficits are real. At least, they are not measured correctly. For example, an iPhone is $1000. Assembly and parts cost about $400 (https://www.digitimes.com/news/a20241004PD214/apple-iphone-component-cost-production-profit.html#:~:text=The%20bill%20of%20materials%20(BOM,up%2016%25%20of%20the%20BOM.) The rest is the cost of design, software, IP that was created in the USA. Even for many parts the value is mostly created in the US (eg Qualcomm modems, memory and storage). When this iPhone is sold in the rest of the world, it effectively exports hundreds of dollars of added value created in the US.

pandadogunited

>The problem isn’t people assuming the market will give good returns in a decade or two. That’s almost certain.  It’s not almost certain, though. There have been multiple decade+ periods where the market was flat. I know [1901-1920,](https://testfol.io/?s=37zzndvPNPF), [1929-1943](https://testfol.io/?s=fTKrh0PD0nE), [1966-1984](https://testfol.io/?s=76qwMr5Q0AU), and [2000-2013](https://testfol.io/?s=deJdJD4Kmo1) off the top of my head, so there are probably more.

leesteapleton

That Garcia wifebeater was involved in a human trafficking stop in 2022 in TN where the FBI had to step in and tell the local PD to piss off. That’s why they care about him and not the other thousands of others getting the boot

kittypryde123

PD not ID

alefkandra

calls on $PD then cuz any on call dev is being paged to fuck right now

Strickschal

> We will see about that… We already ARE seeing about that. If we look at Germany, net migration is only around 2000 people per year and the trend of the absolute numbers is negative, which I wouldn't expect to change anytime soon. Also, more US americans move to Germany than Germans move to the US. https://www.destatis.de/DE/Presse/Pressemitteilungen/2024/10/PD24_N048_12_91.html > traditionally, people move to where they can make the most money as long as they have the opportunity to actually move. Is that so or is that just what you believe? Again, there are lots of reasons besides money to not move halfway across the world in general and to not move to the US in particular. > I know many a European that lives in the US working high paid jobs, they only came here in the first place because of the money and opportunity. Many more try to come to the US after school, then have to move back and work the same job in Europe making half as much. Sure these people exist, but drawing the conclusion that there's no people left here who could develop alternatives to Google, Amazon and whatnot is quite the leap, to say the least.

Captain_of_Gravyboat

The cost to manufacture an iPhone is around $500. https://www.digitimes.com/news/a20241004PD214/apple-iphone-component-cost-production-profit.html Before tariffs they were getting about 60% profit margin on the sale of the phone itself (not including services, subscriptions, kickbacks from carriers for exclusives, etc..) so im pretty sure they will be ok and will be quite thrilled if people are ready to pay $2300. The tariff will be on the declared value of goods at point of import (basically cost + shipping), not on the retail price.

yuseyername

Sorry don’t know where to post this. OP keeps sexually harassing my backyard chickens. Pittsburgh PD said they can’t do anything about it yet, but I want you guys to know OP keeps sneaking into my yard to fuck my chickens.

x_Carlos_Danger_x

DOGE cuts and donuts finally caught up the local PD 🚔

chargedcapacitor

Dallas PD covered it up because of their gigantic lack of competence. It's not even a secret, they keep some of the records sealed because some of the idiots or their families are still alive and the government doesn't want to put them in harms way

BumblesAZ

I’m sure the HOA’s are going to have a field day with issuing violations on the residential farms. Also, that’s not to mention the nuisance calls the local PD’s are going to deal with when the boomers start calling on their neighbors about blowing chicken shit. lol

North_Ad_4609

I took a lot of beating trying to tell people that this was a bad PD based on nothing but lies. It pumped like they always do and dumped really hard too. This was the making of that op Best_phone.

eddie991ao

Tacoma PD will make you cry

MoonsofPluto

I've just realized I had the most ridiculous run of luck then , I wasn't really paying much attention to the economy except the news were always banging on about banks and all that stuff. I managed to double my salary 4 x almost in a row during that time. I went from £22k a year 2008 as a junior to £42k a year moving jobs 2009 then went free lancer contracting and made more than double again £400 PD 2010 and 2011. I then went to Switzerland in 2012 and after tax was earning about double the amount again because it was a great rate and the tax rate there is so low.. I've never earned as much since then. Which was 2014

mountainoftea

Here's an interesting tidbit: [https://www.digitimes.com/news/a20250305PD239/psmc-himax-display-manufacturing-technology.html](https://www.digitimes.com/news/a20250305PD239/psmc-himax-display-manufacturing-technology.html)

wambulancer

Ah yes the time-honored tradition of PDs taking huge white elephant boondoggles that do nothing but drain resources You gotta be a grade-A moron police chief to accept these things when they'll be waterlogged paperweights within a year if given the usual PD maintenance schedule

WildConsideration376

Lunr had a warrant out for arrest by the stock market police..so they decided to call the PD and pay the fee for the warrant to avoid getting arrested on the way to Wendy's work shift.Thanks..and you are welcome

_Christopher_Crypto

They did it last time I was there. We always use the app to scan and pay, we still have to wait in the line with all of the checkout users. They will scan their items but not ours. It would be great if they opened both sides of the tower and let self checkout walk through. The one we frequent has the local PD there arresting shoplifters more often than not so that may be a deterrent for them.

kidfromtheast

So, 5 days ago there is delivery delays and actual yield issues of GB200. Now, we magically have tons of GB200 chips repurposed for 5090? Are we willing in the world magic? https://www.digitimes.com/news/a20250211PD210/quanta-foxconn-nvidia-blackwell-2025.html